The number of tumor-infiltrating GrB+ effector CD8a+ T cells was highest in mice treated with combinations of αPD-1 plus celecoxib or CAY10678 and somewhat increased in mice treated with αPD-1, celecoxib, or CAY10678 monotherapy (Fig. 6C). This evidence concerns the gene CD8A and neoplasm.